An FDA-Drug Library Screen for Compounds with Bioactivities Against Meticillin-Resistant Staphylococcus Aureus (MRSA)

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2016 Mar 31

PMID 27025633

Citations 7

Authors

Qiu Ying Lau

Yoke Yan Fion Tan

Vanessa Chai Yin Goh

David Jing Qin Lee

Fui Mee Ng

Esther H Q Ong

Jeffrey Hill

Cheng San Brian Chia

Affiliations

Soon will be listed here.

Abstract

The lack of new antibacterial drugs entering the market and their misuse have resulted in the emergence of drug-resistant bacteria, posing a major health crisis worldwide. In particular, meticillin-resistant Staphylococcus aureus (MRSA), a pathogen responsible for numerous human infections, has become endemic in hospitals worldwide. Drug repurposing, the finding of new therapeutic indications for approved drugs, is deemed a plausible solution to accelerate drug discovery and development in this area. Towards this end, we screened 1163 drugs approved by the Food and Drug Administration (FDA) for bioactivities against MRSA in a 10 μM single-point assay. After excluding known antibiotics and antiseptics, six compounds were identified and their MICs were determined against a panel of clinical MRSA strains. A toxicity assay using human keratinocytes was also conducted to gauge their potential for repurposing as topical agents for treating MRSA skin infections.

Citing Articles

High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.

Ayon N Metabolites. 2023; 13(5).

PMID: 37233666 PMC: 10220967. DOI: 10.3390/metabo13050625.

A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection.

Vazquez-Rodriguez J, Shaqour B, Guarch-Perez C, Choinska E, Riool M, Verleije B Sci Rep. 2022; 12(1):12329.

PMID: 35854044 PMC: 9296466. DOI: 10.1038/s41598-022-16107-4.

Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.

Weiss A, Delavenne E, Matias C, Lagler H, Simon D, Li P Clin Transl Med. 2022; 12(5):e790.

PMID: 35522900 PMC: 9076020. DOI: 10.1002/ctm2.790.

Optimization of a High-Throughput 384-Well Plate-Based Screening Platform with ATCC 25923 and ATCC 15442 Biofilms.

Gilbert-Girard S, Savijoki K, Yli-Kauhaluoma J, Fallarero A Int J Mol Sci. 2020; 21(9).

PMID: 32344836 PMC: 7246797. DOI: 10.3390/ijms21093034.

The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.

Yeo W, Arya R, Kim K, Jeong H, Cho K, Bae T Sci Rep. 2018; 8(1):2521.

PMID: 29410445 PMC: 5802796. DOI: 10.1038/s41598-018-20617-5.

References

MacDonald M, Lamerdin J, Owens S, Keon B, Bilter G, Shang Z . Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006; 2(6):329-37. DOI: 10.1038/nchembio790. View

Pearson R, Hewlett E . Niclosamide therapy for tapeworm infections. Ann Intern Med. 1985; 102(4):550-1. DOI: 10.7326/0003-4819-102-4-550. View

Silver L . Challenges of antibacterial discovery. Clin Microbiol Rev. 2011; 24(1):71-109. PMC: 3021209. DOI: 10.1128/CMR.00030-10. View

Wertheim H, Melles D, Vos M, van Leeuwen W, van Belkum A, Verbrugh H . The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005; 5(12):751-62. DOI: 10.1016/S1473-3099(05)70295-4. View

Janssen P, NIEMEGEERS C, SCHELLEKENS K, Lenaerts F, VERBRUGGEN F, VAN NUETEN J . The pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug. Eur J Pharmacol. 1970; 11(2):139-54. DOI: 10.1016/0014-2999(70)90043-9. View

Appelbaum P . Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2007; 30(5):398-408. DOI: 10.1016/j.ijantimicag.2007.07.011. View

Power D, Kemeny N . The role of floxuridine in metastatic liver disease. Mol Cancer Ther. 2009; 8(5):1015-25. DOI: 10.1158/1535-7163.MCT-08-0709. View

Kinch M, Patridge E, Plummer M, Hoyer D . An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov Today. 2014; 19(9):1283-7. DOI: 10.1016/j.drudis.2014.07.005. View

Gould I . Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents. 2006; 28(5):379-84. DOI: 10.1016/j.ijantimicag.2006.09.001. View

10.

Oprea T, Mestres J . Drug repurposing: far beyond new targets for old drugs. AAPS J. 2012; 14(4):759-63. PMC: 3475856. DOI: 10.1208/s12248-012-9390-1. View

11.

Gould I . MRSA bacteraemia. Int J Antimicrob Agents. 2007; 30 Suppl 1:S66-70. DOI: 10.1016/j.ijantimicag.2007.06.023. View

12.

Berger F, Berger S . Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years?. Cancer Biol Ther. 2006; 5(9):1238-41. DOI: 10.4161/cbt.5.9.3414. View

13.

Brenner R, Ellis-Grosse E, Echols R . Moving goalposts--regulatory oversight of antibacterial drugs. Nat Biotechnol. 2006; 24(12):1515-20. DOI: 10.1038/nbt1206-1515. View

14.

Boyce J, Havill N, Otter J, Adams N . Widespread environmental contamination associated with patients with diarrhea and methicillin-resistant Staphylococcus aureus colonization of the gastrointestinal tract. Infect Control Hosp Epidemiol. 2007; 28(10):1142-7. DOI: 10.1086/520737. View

15.

Rimland D, Roberson B . Gastrointestinal carriage of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 1986; 24(1):137-8. PMC: 268848. DOI: 10.1128/jcm.24.1.137-138.1986. View

16.

Fernandes P . Antibacterial discovery and development--the failure of success?. Nat Biotechnol. 2006; 24(12):1497-503. DOI: 10.1038/nbt1206-1497. View

17.

Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R . Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18-55. DOI: 10.1093/cid/ciq146. View

18.

Reznikov L, Abou Alaiwa M, Dohrn C, Gansemer N, Diekema D, Stoltz D . Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros. 2014; 13(5):515-9. PMC: 4718582. DOI: 10.1016/j.jcf.2014.02.004. View

19.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P . Tackling antibiotic resistance. Nat Rev Microbiol. 2011; 9(12):894-6. PMC: 4206945. DOI: 10.1038/nrmicro2693. View

20.

Lee B, Singh A, David M, Bartsch S, Slayton R, Huang S . The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2012; 19(6):528-36. PMC: 3463640. DOI: 10.1111/j.1469-0691.2012.03914.x. View